DK1699459T3 - Fremgangsmåde til behandling af multipel sclerose - Google Patents

Fremgangsmåde til behandling af multipel sclerose

Info

Publication number: DK1699459T3
Authority: DK; Denmark
Prior art keywords: multiple sclerosis; meca; treating multiple; a3rag; apnea
Prior art date: 2003-12-29

Application number

DK04806691T

Other languages

Danish (da)

English (en)

Inventor

Pnina Fishman

Yehuda Sara Bar

Lea Madi

Original Assignee

Can Fite Biopharma Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-12-29

Filing date

2004-12-23

Publication date

2007-10-08

2004-12-23 Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd

2007-10-08 Application granted granted Critical

2007-10-08 Publication of DK1699459T3 publication Critical patent/DK1699459T3/da

Links

201000006417 multiple sclerosis Diseases 0.000 title abstract 2
229940122614 Adenosine receptor agonist Drugs 0.000 abstract 3
239000003379 purinergic P1 receptor agonist Substances 0.000 abstract 3
IPSYPUKKXMNCNQ-PFHKOEEOSA-N (2s,3s,4r,5r)-5-[2-chloro-6-[(3-iodophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC(Cl)=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 IPSYPUKKXMNCNQ-PFHKOEEOSA-N 0.000 abstract 1
LDYMCRRFCMRFKB-MOROJQBDSA-N (2s,3s,4r,5r)-5-[6-[(4-aminophenyl)methylamino]purin-9-yl]-3,4-dihydroxy-n-methyloxolane-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=CC(N)=CC=3)=C2N=C1 LDYMCRRFCMRFKB-MOROJQBDSA-N 0.000 abstract 1
HUJXGQILHAUCCV-MOROJQBDSA-N 3-iodobenzyl-5'-N-methylcarboxamidoadenosine Chemical compound O[C@@H]1[C@H](O)[C@@H](C(=O)NC)O[C@H]1N1C2=NC=NC(NCC=3C=C(I)C=CC=3)=C2N=C1 HUJXGQILHAUCCV-MOROJQBDSA-N 0.000 abstract 1
101150046889 ADORA3 gene Proteins 0.000 abstract 1
208000008784 apnea Diseases 0.000 abstract 1
239000003937 drug carrier Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Preliminary Treatment Of Fibers (AREA)
Spinning Or Twisting Of Yarns (AREA)
Treatment Of Fiber Materials (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)
Sewing Machines And Sewing (AREA)

DK04806691T 2003-12-29 2004-12-23 Fremgangsmåde til behandling af multipel sclerose DK1699459T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US53271203P	2003-12-29	2003-12-29
PCT/IL2004/001160 WO2005063246A1 (en)	2003-12-29	2004-12-23	Method for treatment of multiple sclerosis

Publications (1)

Publication Number	Publication Date
DK1699459T3 true DK1699459T3 (da)	2007-10-08

Family

ID=34738826

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK04806691T DK1699459T3 (da)	2003-12-29	2004-12-23	Fremgangsmåde til behandling af multipel sclerose

Country Status (10)

Country	Link
US (1)	US7465715B2 (de)
EP (1)	EP1699459B1 (de)
JP (1)	JP2007517019A (de)
CN (1)	CN100423723C (de)
AT (1)	ATE363907T1 (de)
DE (1)	DE602004006895T2 (de)
DK (1)	DK1699459T3 (de)
ES (1)	ES2287804T3 (de)
PL (1)	PL1699459T3 (de)
WO (1)	WO2005063246A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GT200500281A (es) *	2004-10-22	2006-04-24	Novartis Ag	Compuestos organicos.
KR20070090222A (ko)	2004-12-02	2007-09-05	캔-파이트 바이오파마 리미티드	염증에 대한 생물학적 마커
GB0500785D0 (en) *	2005-01-14	2005-02-23	Novartis Ag	Organic compounds
CN101410114B (zh)	2006-01-26	2012-07-04	美国政府卫生与公共服务部	A3腺苷受体别构调节剂
EP2322525B1 (de) *	2006-04-21	2013-09-18	Novartis AG	Purinderivate als Adenosin A2A Rezeptoragonisten
GB0607950D0 (en)	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607944D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
GB0607953D0 (en) *	2006-04-21	2006-05-31	Novartis Ag	Organic compounds
EP1889846A1 (de)	2006-07-13	2008-02-20	Novartis AG	Purinderivate als A2a Agonisten
EP1903044A1 (de) *	2006-09-14	2008-03-26	Novartis AG	Adenosinderivate als Agonisten des A2A-Rezeptors
CA2669108A1 (en) *	2006-11-10	2008-05-15	Novartis Ag	Cyclopentene diol monoacetate derivatives
US9102698B2 (en)	2007-03-14	2015-08-11	Can-Fite Biopharma Ltd.	Process for the synthesis of IB-MECA
US20090088403A1 (en) *	2007-05-07	2009-04-02	Randy Blakely	A3 adenosine receptors as targets for the modulation of central serotonergic signaling
WO2011010306A1 (en)	2009-07-21	2011-01-27	Ramot At Tel-Aviv University Ltd.	A3 adenosine receptor ligands for modulation of pigmentation
IL200753A (en)	2009-09-06	2015-06-30	Can Fite Biopharma Ltd	Pharmaceutical preparation containing ib – meca for the treatment of psoriasis
US20140194308A1 (en) *	2011-04-22	2014-07-10	Kyoto University	Use of myelin basic protein as a novel genetic factor for rheumatoid arthritis
UA117095C2 (uk)	2011-12-22	2018-06-25	Аліос Біофарма, Інк.	Нуклеозидна сполука або її фармацевтично прийнятна сіль
CN104159589A (zh) *	2012-01-23	2014-11-19	坎-菲特生物药物有限公司	肝脏状况的治疗
US9441007B2 (en)	2012-03-21	2016-09-13	Alios Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en)	2012-03-21	2020-08-25	Janssen Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
KR102445887B1 (ko) *	2016-04-21	2022-09-21	아스트로사이트 파마슈티컬스, 인코포레이티드	신경계 및 심혈관계 병태 치료를 위한 화합물 및 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5310732A (en) *	1986-02-03	1994-05-10	The Scripps Research Institute	2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis
DE69428536T2 (de) *	1993-07-13	2002-06-06	The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	A3 -adenosin -rezeptor agonisten
WO1995011681A1 (en)	1993-10-29	1995-05-04	Merck & Co., Inc.	Human adenosine receptor antagonists
WO1997033879A1 (en)	1996-03-15	1997-09-18	Merck & Co., Inc.	Compounds and methods for selectively inhibiting activation of the human a3 adenosine receptor
YU44900A (sh) *	1998-01-31	2003-01-31	Glaxo Group Limited	Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
US6117878A (en) *	1998-02-24	2000-09-12	University Of Virginia	8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6303619B1 (en) *	1998-03-12	2001-10-16	University Of Virginia	Meta-substituted acidic 8-phenylxanthine antagonists of A3 human adenosine receptors
US7160890B2 (en) *	1999-12-02	2007-01-09	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A3 receptor and uses thereof
CZ294538B6 (cs) *	2002-12-30	2005-01-12	Ústav Experimentální Botaniky Akademie Vědčeské Re	Substituční deriváty N6-benzyladenosinu, způsob jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující

2004
- 2004-12-23 DE DE602004006895T patent/DE602004006895T2/de not_active Expired - Fee Related
- 2004-12-23 US US10/521,193 patent/US7465715B2/en not_active Expired - Fee Related
- 2004-12-23 EP EP04806691A patent/EP1699459B1/de not_active Expired - Lifetime
- 2004-12-23 AT AT04806691T patent/ATE363907T1/de not_active IP Right Cessation
- 2004-12-23 JP JP2006546475A patent/JP2007517019A/ja not_active Withdrawn
- 2004-12-23 PL PL04806691T patent/PL1699459T3/pl unknown
- 2004-12-23 CN CNB2004800393344A patent/CN100423723C/zh not_active Expired - Fee Related
- 2004-12-23 WO PCT/IL2004/001160 patent/WO2005063246A1/en not_active Ceased
- 2004-12-23 ES ES04806691T patent/ES2287804T3/es not_active Expired - Lifetime
- 2004-12-23 DK DK04806691T patent/DK1699459T3/da active

Also Published As

Publication number	Publication date
US20060142237A1 (en)	2006-06-29
JP2007517019A (ja)	2007-06-28
ATE363907T1 (de)	2007-06-15
EP1699459B1 (de)	2007-06-06
CN1901915A (zh)	2007-01-24
ES2287804T3 (es)	2007-12-16
PL1699459T3 (pl)	2007-12-31
DE602004006895D1 (de)	2007-07-19
US7465715B2 (en)	2008-12-16
DE602004006895T2 (de)	2008-01-31
WO2005063246A1 (en)	2005-07-14
CN100423723C (zh)	2008-10-08
EP1699459A1 (de)	2006-09-13

Similar Documents

Publication	Publication Date	Title
DK1699459T3 (da)	2007-10-08	Fremgangsmåde til behandling af multipel sclerose
MY146986A (en)	2012-10-15	Methods for treating interleukin-6 related diseases
BRPI0418112A (pt)	2007-04-17	inibidores de p-38 quinase bicìclico heterocìclicos
NO20070514L (no)	2007-03-12	Pyrrolotriazin kinase inhibitorer
JO2755B1 (en)	2014-03-15	(Use 2-6- (3-amino-piperidine-1-yl) -3-methyl-2, 4-dioxo-3,4-dihydro-2H-pyrimidine-1-y-methyl-4-fluoro-benzonitrile for the treatment of diabetes, cancer , Autoimmune disorders and HIV infection)
LU92323I2 (fr)	2015-09-22	La combinaison de (a) dextromethorphan ou un de ses sels pharmaceutiquement acceptables, précursers ou dérivés, par ex. hydrobromure de dextromethorphan et en particulier hydrobromure de dextromethorphan monohydrate;et (b) quinidine ou un de ses selspharmacuetiquement acceptables, précurseurs ou dé rivés, par ex. sulfate de quinidine et en particulier sulfate de quinidine dihydrate
NO20071446L (no)	2007-03-26	Endotelin A reseptor (ETA)-antagonister i kombinasjon med fosfodiesterase 5-inhibitorer (PDE5) og anvendelser derav.
EA200601160A1 (ru)	2006-12-29	2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов
AU2003296993A8 (en)	2004-07-09	Cyclopropyl compounds as ccr5 antagonists
NO20052496D0 (no)	2005-05-24	Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
BR0306583A (pt)	2004-11-30	Provisão e sincronização da lista de viagem preferida e do indicador de viagem
WO2007117973A3 (en)	2008-07-17	Multiple-listing referral-tracking system
NO20085099L (no)	2009-02-16	Puritonderivativer som HM74A agonister
EA200401227A1 (ru)	2005-04-28	Система доставки лекарства с контролируемым высвобождением, включающая правастатин
GEP20247585B (en)	2024-01-25	Furoindazole derivatives
WO2006002437A3 (en)	2006-12-28	Treatment of conditions involving demyelination
BRPI0516003A (pt)	2008-04-29	composto, uso em um composto ou um éster, um sal farmaceuticamente aceitável ou um hidrato do mesmo, formulação farmacêutica, e, método para a triagem in vitro de ligandos de receptor de prostanóide seletivos
HUP0401805A2 (hu)	2004-12-28	Pulmonális betegségek kezelésére szolgáló vegyületek
NO20065762L (no)	2007-02-12	Prodroger av pyrrolypyrimidin-ERK-proteinkinaseinhibitorer.
WO2003072572A8 (en)	2004-01-29	Beta3-adrenergic receptor agonists
NO20060958L (no)	2006-04-25	Farmasoytisk preparat
PH12022551294A1 (en)	2023-11-20	Methods of treating pulmonary arterial hypertension
DK1841765T5 (da)	2009-12-21	Imidazo[4,5-C]pyridinforbindelse og fremgangsmåde til antiviral behandling
WO2003094957A3 (en)	2004-02-12	Methods of therapy for inducing tolerance
TWI256388B (en)	2006-06-11	Pharmaceutical combination